Discounted Cash Flow (DCF) Analysis Unlevered

BioXcel Therapeutics, Inc. (BTAI)

$2.49

-0.25 (-9.12%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 2.49 | undervalue

Operating Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 2.49
Beta 0.990
Diluted Shares Outstanding 28.02
Cost of Debt
Tax Rate -3.68
After-tax Cost of Debt 8.72%
Risk-Free Rate
Market Risk Premium
Cost of Equity 9.268
Total Debt 94.16
Total Equity 69.76
Total Capital 163.91
Debt Weighting 57.44
Equity Weighting 42.56
Wacc

Build Up Free Cash

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%1.92%0.20%0.28%-3.68%-0.26%-0.26%-0.26%-0.26%-0.26%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0.34-0.87-0.32-0.45-0.14-----
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 8.95
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -99.57
Equity Value -
Shares Outstanding 28.02
Equity Value Per Share -